TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05794659: Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer

Sponsor: Aston Sci. Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 98 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT05794659 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05794659 Rescue Dossier →